McKesson stock heads into the open after a 1.5 percent slide

At the close on September 4, 2026, McKesson stock finished at USD 907.99 on the NYSE, down 1.45 percent from the prior session. McKesson stock lagged the S&P 500, which fell about 0.4 percent that day, as investors weighed a USD 2.25 billion precision medicine deal.

McKesson stock closed at USD 907.99 on the NYSE on September 4, 2026, down 1.45 percent from the previous close of USD 921.38 based on official NYSE data. The shares underperformed the S&P 500 benchmark, which slipped about 0.4 percent in the same session, pointing to relative weakness in McKesson against the broader large cap market.

September 4, 2026 in numbers

McKesson Corp. (ISIN US58155Q1031, NYSE: MCK) closed the September 4, 2026 session at USD 907.99, a decline of USD 13.39 or 1.45 percent compared with the prior close of USD 921.38, according to NYSE closing figures cited in a Barrons market overview referenced by ad hoc corporate news. Intraday trading kept the stock in a narrow range, with a low near USD 907.99 and a high close to USD 921, while reported turnover stood around 879,000 shares, roughly 86% of the recent 65 day average volume, per that same session profile. On the broader market side, the S&P 500 benchmark index finished the September 4, 2026 session down about 0.4 percent, meaning McKesson lagged the large cap average in that risk off environment.

Sector commentary in early September highlighted that investors are watching McKesson’s oncology and multi specialty operations and a planned precision medicine acquisition valued at approximately USD 2.25 billion as longer term growth drivers rather than trading solely on near term data points for the September 4, 2026 move, as summarized in the ad hoc corporate wrap that drew on analysis from MarketBeat. In a separate report, Outsource Accelerator noted that McKesson has agreed to acquire Precision Medicine Group from Blackstone for approximately USD 2.25 billion, adding biomarker intelligence, laboratory services and a global contract research organization to its oncology and specialty care portfolio, with closing subject to customary regulatory clearances.

Precision medicine deal and events today

According to Outsource Accelerator, McKesson said the Precision Medicine Group acquisition aligns with its strategy of concentrating capital in oncology and specialty care, with its Oncology and Multispecialty segment generating USD 14.2 billion in fiscal first quarter 2026 revenue, a 33 percent year over year increase, underscoring the strategic weight of this growth axis. Commentary cited by the ad hoc corporate news wrap indicated that this potential USD 2.25 billion precision medicine deal was among the themes investors weighed alongside broader market volatility during the recent slide in McKesson shares on September 4, 2026.

While no specific company earnings or dividend events for McKesson are scheduled for September 10, 2026 in the available reports, the precision medicine transaction and the focus on oncology expansion remain key storylines that could shape sentiment today as trading resumes ahead of the opening bell. Broader macro factors, including recent declines in major US equity indices described in market news coverage, continue to form the backdrop for defensive healthcare distributors such as McKesson as investors assess risk appetite going into today’s session.